Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ESSA Pharma Inc. (EPIX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8500+0.0700 (+3.93%)
At close: 04:00PM EDT
1.9300 +0.08 (+4.32%)
After hours: 05:42PM EDT
Advertisement
Full screen
Loading interactive chart...
  • CNW Group

    ESSA Pharma Appoints Philip Kantoff to its Board of Directors

    ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors. Dr. Kantoff brings invaluable insight and experience to ESSA as a renowned medical oncologist and leader in the clinical development of new prostate cancer treatments.

  • Investopedia

    Examining Penny Stocks with Technical Analysis for September 2022

    Technical analysis (TA) involves the careful study of a stock's chart patterns and trends. Although this set of skills may seem daunting at first, even beginners can incorporate a few select TA methodologies into their investing strategy to great success.

  • Zacks Small Cap Research

    EPIX: Multiple Ongoing Studies of EPI-7386…

    By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Multiple Ongoing Studies of EPI-7386 ESSA Pharma Inc (NASDAQ:EPIX) is developing EPI-7386 as a treatment for prostate cancer. It is a member of a novel class of compounds known as ‘anitens’, which specifically target the androgen receptor (AR). The AR is the main signaling mechanism driving the growth of prostate

Advertisement
Advertisement